Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment.  They found that nivolumab was associated with longer survival time in patients that responded to treatment.  Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Evaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma

Posted by on Aug 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug

Posted by on Aug 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment.  The details Both multiple myeloma (MM) and non-Hodkin lymphoma...

Read More

Evaluating BCD chemotherapy for patients with peripheral T-cell lymphoma

Posted by on Jul 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...

Read More

Searching patients with relapsed or unresponsive cancer to test a new medication

Posted by on Jul 31, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors.  The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states.  The details Relapsed/refractory (R/R) cancer is a term for...

Read More

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Posted by on Jul 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...

Read More

Quizartinib in the treatment of relapsed or unresponsive acute myeloid leukemia

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of quizartinib compared to chemotherapy in the treatment of relapsed or unresponsive acute myeloid leukemia (AML). Researchers found that quizartinib was safer and more effective than chemotherapy in these patients. Some background Acute myeloid leukemia (AML) is a cancer of the bone...

Read More

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Posted by on Jul 9, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...

Read More